Renalytix AI PLC, which is working on developing artificial intelligence (AI) to support clinical decision making in kidney disease patients, has filed Form S-1 Registration Statement on June 24, 2020 with the U.S. Securities and Exchange Commission to raise up to $86 million in an IPO. No pricing terms were disclosed.
The Cardiff, United Kingdom-based company was founded in 2018 and plans to list on the Nasdaq Global Market under the symbol “RNLX.” The company is currently listed in London on the AIM under the ticker “RENX”; it closed Wednesday with a market cap of £303 million ($377 million).
J.P. Morgan and Stifel are the joint bookrunners on the deal.
The company engages Cooley LLP as US Securities Counsel, and Deloitte & Touche LLP as Independent Auditor.
Hexcellence Consulting has experienced IPO consulting team focus on listing in US Stock Market,
namely NYSE, Nasdaq and OTC Markets.
Should you interested to list your company in US Stock Market,
please contact us at [email protected].